---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-157940"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2026-04-16T23:59:59+00:00"
generated_at: "2026-05-15T05:51:16.326236+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xilio Therapeutics appoints Cheryl Blanchard to Board; Rossi resigns

## Summary
- Cheryl Blanchard elected as Class III director effective April 15, 2026; term expires at 2027 annual meeting.
- Blanchard appointed chair of Compensation Committee and member of Audit Committee.
- Blanchard receives $40k annual cash retainer, $12k for Comp chair, $7.5k for Audit; initial option for 10k shares vesting over 3 years.
- Christina Rossi resigned from Board on April 15, 2026; resignation not due to any disagreement with company.
- Board adopted amended Non-Employee Director Compensation Policy effective April 15, 2026 (Exhibit 10.1).

## SEC filing metadata
- accession: 0001193125-26-157940
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2026-04-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000119312526157940/0001193125-26-157940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000119312526157940/xlo-20260416.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-157940
- JSON: https://secwatch.observer/filing/0001193125-26-157940.json
- Plain text: https://secwatch.observer/filing/0001193125-26-157940.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.